272 related articles for article (PubMed ID: 35080601)
1. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting.
Di Palo KE; Sinnett MJ; Goriacko P
JAMA Netw Open; 2022 Jan; 5(1):e2145236. PubMed ID: 35080601
[TBL] [Abstract][Full Text] [Related]
2. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
3. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study.
Rafique Z; Liu M; Staggers KA; Minard CG; Peacock WF
Acad Emerg Med; 2020 Jan; 27(1):54-60. PubMed ID: 31599043
[TBL] [Abstract][Full Text] [Related]
4. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
5. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
Meaney CJ; Beccari MV; Yang Y; Zhao J
Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
[TBL] [Abstract][Full Text] [Related]
8. Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.
Pergola PE; Spiegel DM; Warren S; Yuan J; Weir MR
Am J Nephrol; 2017; 46(4):323-332. PubMed ID: 29017162
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia.
Rydell A; Thackrey C; Molki M; Mullins BP
Ann Pharmacother; 2023 Nov; ():10600280231209968. PubMed ID: 37953506
[TBL] [Abstract][Full Text] [Related]
10. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
Piña IL; Yuan J; Ackourey G; Ventura H
Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
[TBL] [Abstract][Full Text] [Related]
11. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
12. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
13. Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.
Bushinsky DA; Budden JJ; Kalra PA; Yuan J; Quinn CM; Epstein M
Am J Kidney Dis; 2023 Jul; 82(1):97-104. PubMed ID: 36965827
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia.
Li L; Harrison SD; Cope MJ; Park C; Lee L; Salaymeh F; Madsen D; Benton WW; Berman L; Buysse J
J Cardiovasc Pharmacol Ther; 2016 Sep; 21(5):456-65. PubMed ID: 26856345
[TBL] [Abstract][Full Text] [Related]
15. Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.
Bushinsky DA; Spiegel DM; Yuan J; Warren S; Fogli J; Pergola PE
Clin J Am Soc Nephrol; 2019 Jan; 14(1):103-110. PubMed ID: 30381412
[TBL] [Abstract][Full Text] [Related]
16. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
17. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
18. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.
Bushinsky DA; Williams GH; Pitt B; Weir MR; Freeman MW; Garza D; Stasiv Y; Li E; Berman L; Bakris GL
Kidney Int; 2015 Dec; 88(6):1427-1433. PubMed ID: 26376130
[TBL] [Abstract][Full Text] [Related]
19. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
Epstein M; Pitt B
Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
